Cell Therapy News/Articles, page-18038

Another interesting link is this, given that MSCs and MPCs are treatments rather no than drugs in a traditional sense. This means that they need a clinical setting to be administered. This article looks at the economic model of ambulatory surgical “centers” in the US. These outpatient centres are ideal for the company’s treatments to take place. Surgcenter is in this business, and Tenet, which bought through its subsidiary USPI almost 100 of these ASCs from Surgcenter, is investing a lot of capital in these centres. In fact, the two parties are in year 3 of a 5 year agreement to develop a number of the centres. (I presume when they are at a certain point of maturity, they will be transferred to USPI at a pre-agreed price against the original sale agreement.) GG of course knows how these centres make their profits and how there wpuld be synergistic benefits from acquiring a stake in a company developing innovative treatments in CLBP and other diseases:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790806/

I believe it will be a matter of time when these benefits are realised for both Tenet/Surgcenter and MSB.

https://www.beckersasc.com/asc-news/how-tenet-became-a-household-name-for-ascs.html

DYOR